{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
An observational, cross-sectional survey to explore the expanding role of Xanthines beyond their traditional use in bronchodilation within routine clinical practice
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Survey Questionnaire Form

  1. How many cases of COPD are seen in your practice every month? *

  2. Discuss about role of methylxanthines in COPD. *
  3. When do you prefer to use methylxanthines in patients with COPD? *
  4. What percent of COPD patients require methylxanthines in your clinical practice? *
  5. Which is the most common patient characteristic in those who require methylxanthines? (age, comorbidity, severity, smoker)*
  6. Compare and contrast between available methylxanthines based on your clinical experience. *
    7. Duration of action Dose Route of administration Frequency of dosing

    Doxophylline

    Acebrophylline

    Theophylline

    Aminophylline

  7. Over the years, use of methylxanthines in your clinical practice has *

  8. Explain what has led to increased/decreased utilization of methylxanthines? *
  9. Rate different options available for methylxanthines considering overall efficacy and safety from 0-5 (0 being the worst, 5 being the best) *
    10. Rating
  10. How do you rate the effectiveness of available methylxanthines based on mucoregulator effect, rating from 0-5 (0 being the worst, 5 being the best) *
    11. Rating
  11. How do you rate the effectiveness of available methylxanthines based on bronchodilatory effect, rating from 0-5 (0 being the worst, 5 being the best) *
    12. Rating
  12. What is the utilization of each methylxanthine for bronchodilator effect in your clinical practice? (in percentage) *
    13. Utilization (in percentage)
    {{-- --}} %
    %
    %
    %
  13. What is the utilization of each methylxanthine for mucoregulator effect in your clinical practice? (in percentage) *
    14. Utilization (in percentage)
    %
    %
    %
    %
  14. What is the utilization of each methylxanthine for anti-inflammatory effect in your clinical practice? (in percentage) *
    15. Utilization (in percentage)
    %
    %
    %
    %
  15. Compare safety of methylxanthine from available options? (0 being the least safe, 5 being the most safe) *
    16. {{-- --}}
    %
  16. Is COPD most common indication for use of methylxanthines? *
  17. In what other conditions are methylxanthines utilized? *
    18. Other conditions where methylxanthines are useful (except COPD) Number of patients every month for each condition where corresponding treatment is prescribed Reason for using it in that particular condition (mucoregulator/ bronchodilator/ anti-inflammatory)
  18. Do you believe there is sufficient clinical evidence for the use of acebrophylline in COPD? *

  19. Acebrophylline is preferred in how much proportion of COPD patients in your clinical practice? *

  20. In COPD, which is the patient profile where acebrophylline is the drug of choice? *
  21. When do you prefer Acebrophylline treatment based on disease severity in your clinical practice? *

  22. Approximately, how many patients require acebrophylline in your clinical practice every month? *

  23. What makes acebrophylline drug of choice over other xanthine derivatives? (Select all that apply) *

  24. Does acebrophylline improve shortness of breath better than other xanthine derivatives in COPD? *

  25. Does acebrophylline reduce frequency of reliever medications better than other xanthine derivatives in COPD patients?*

  26. Does acebrophylline reduce sputum production more than other xanthine derivatives in COPD patients? *

  27. Based on your clinical experience, which xanthine derivative leads to highest reduction in FEV1?*
  28. As per your clinical expertise, which xanthine derivative leads to highest reduction in exacerbations? *
  29. Do you agree that acebrophylline has better cardiac safety than other xanthine derivatives in COPD patients? *

  30. What is the preferred duration of therapy of Acebrophylline in COPD in your clinical practice? *

  31. Which clinical symptom improves the most in COPD patients after Acebrophylline treatment as per observations in your clinical practice? (Select all that apply) *

  32. Is there any need for concomitant mucolytic medication along with Acebrophylline in COPD patients? *

  33. How frequently are patients with COPD followed up in your clinical practice? *

  34. Which property of acebrophylline is most beneficial in patients with COPD? (Select all that apply) *

  35. Rate patient satisfaction with Acebrophylline therapy. *

    36. {{-- --}}
  36. What is the dose and frequency of administration of acebrophylline to COPD patients based on severity in your clinical practice? *
    37. Dose Frequency

    Gold 1

    Gold 2

    Gold 3

    Gold 4

  37. What is the dose and frequency of administration of acebrophylline to COPD patients based on groups of COPD in your clinical practice? *
    38. Dose Frequency

    Group A

    Group B

    Group E

  38. How important is lifestyle modification in patients with COPD? *

  39. How frequently are patients with COPD followed up in your practice based on groups? *
    40. Frequency of follow-ups

    Group A

    Group B

    Group E

  40. How frequently are patients with COPD followed up in your practice based on severity? *
    41. Frequency of follow-ups

    Gold 1

    Gold 2

    Gold 3

    Gold 4

  41. Which COPD phenotype is more likely to be prescribed acebrophylline or other xanthine derivatives? *

  42. What, according to your expertise, are the concerns while using acebrophylline in patients with COPD? *
  43. Is there any issue faced with acebrophylline as a molecule in terms of: *

  44. Do you believe the need of any other formulation of acebrophylline to increase patient’s compliance? *
  45. Do you think that combining muco-active agents enhances patient-related outcomes compared to using a single agent? *

  46. If yes, which mucoactive agents are preferred?
  47. How do you typically monitor the effectiveness of muco-active therapy in your patients? (Select all that apply) *

  48. Please provide any additional comments or insights regarding the use of acebrophylline. *